🇺🇸 FDA
Patent

US 11911415

CRISPR/Cas-related methods and compositions for improving transplantation

granted A61KA61K35/28A61P

Quick answer

US patent 11911415 (CRISPR/Cas-related methods and compositions for improving transplantation) held by Editas Medicine, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K35/28, A61P, A61P19/00, A61P3/00